At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 345 enrolled
Drug / intervention
GnRHadrug
Likely dose
GnRHa 3.6mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity in Women With Breast Cancer in China
In Brief
A Phase 3 clinical trial evaluating GnRHa for Breast Cancer. Completed, enrolled 345 participants across 2 sites.
Detailed Summary
This prospective randomized controlled study is conducted to analyze the effect of Goserelin on ovarian function in women with breast cancer in China.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesChina
CollaboratorsZhejiang Cancer Hospital
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 2015
Enrollment StartSep 2015
Primary CompletionJan 2021
TodayJul 2026
First PostedAug 7, 2015
Enrollment StartSep 1, 2015
Primary CompletionJan 12, 2021
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 10.9 years ago
Interventions
GnRHadrug
3.6mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy.